Please use this identifier to cite or link to this item: https://doi.org/10.1002/ehf2.12250
Title: Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF)
Authors: Yeo, Tee Joo 
Yeo, Poh Shuan Daniel
Hadi, Farid Abdul
Cushway, Timothy
Lee, Kim Yee
Yin, Fang Fang
Ching, Anne
Li, Ruili
Loh, Seet Yoong
Lim, Shir Lynn 
Wong, Raymond Ching-Chiew
Tai, Bee Choo 
Richards, Arthur Mark 
Lam, Carolyn SP 
Keywords: Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
Iron deficiency
Southeast Asian heart failure
Ferric carboxymaltose
COST-EFFECTIVENESS ANALYSIS
FERRIC CARBOXYMALTOSE
DEFICIENT PATIENTS
EXERCISE CAPACITY
ANEMIA
PREVALENCE
THERAPY
SAFETY
TRIAL
POPULATION
Issue Date: 1-Apr-2018
Publisher: WILEY PERIODICALS, INC
Citation: Yeo, Tee Joo, Yeo, Poh Shuan Daniel, Hadi, Farid Abdul, Cushway, Timothy, Lee, Kim Yee, Yin, Fang Fang, Ching, Anne, Li, Ruili, Loh, Seet Yoong, Lim, Shir Lynn, Wong, Raymond Ching-Chiew, Tai, Bee Choo, Richards, Arthur Mark, Lam, Carolyn SP (2018-04-01). Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). ESC HEART FAILURE 5 (2) : 344-353. ScholarBank@NUS Repository. https://doi.org/10.1002/ehf2.12250
Abstract: Aims: Iron deficiency is highly prevalent in Southeast Asians with heart failure (HF) and associated with worse outcomes. This trial aimed to assess the effect of intravenous iron in Southeast Asians hospitalized with decompensated HF. Methods and results: Fifty patients hospitalized for acute decompensated HF, regardless of ejection fraction, with iron deficiency (defined as serum ferritin <300 ng/mL if transferrin saturation is <20%) were randomized to receive either one dose of intravenous ferric carboxymaltose (FCM) 1000 mg or placebo (0.9% saline) following HF stabilization and before discharge in two Singapore tertiary centres. The primary endpoint was difference in 6-min walk test (6MWT) distance over 12 weeks, while secondary endpoints were quality of life assessed using validated Kansas City Cardiomyopathy Questionnaire (KCCQ) and Visual Analogue Scale (VAS). Improvement in 6MWT distance at Week 12 was observed in both FCM and placebo groups (from 252 ± 123 to 334 ± 128 m and from 243 ± 67 to 301 ± 83 m, respectively). Unadjusted analysis showed 6MWT distance for FCM exceeded that for placebo, but adjustment for baseline covariates and time attenuated this effect {adjusted mean difference between groups: 0.88 m [95% confidence interval (CI) −30.2 to 32.0, P = 0.956]}. KCCQ overall summary and VAS were similar in both groups [adjusted mean difference: KCCQ −1.48 (95% CI −8.27 to 5.31, P = 0.670) and VAS 0.26 (95% CI −0.33 to 0.86, P = 0.386)]. FCM was well tolerated with no serious treatment-related adverse events. Conclusions: Intravenous FCM administered pre-discharge in Southeast Asians hospitalized with decompensated HF is clinically feasible. Changes in 6MWT distance should be measured beyond Week 12 to account for background therapy effects.
Source Title: ESC HEART FAILURE
URI: https://scholarbank.nus.edu.sg/handle/10635/205913
ISSN: 20555822
DOI: 10.1002/ehf2.12250
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Single-dose intravenous iron in Southeast Asian heart failure patients A pilot randomized placebo-controlled study (PRACTICE.pdf544.69 kBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

14
checked on Aug 8, 2022

Page view(s)

68
checked on Aug 4, 2022

Download(s)

1
checked on Aug 4, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.